Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA

Annals of Hepatology

Volumn 7, Issue 4, 2008, Pages 339-344

  Igetei, Rufina ^a   Otegbayo, Jesse A ^a   Ndububa, Dennis A ^b   Lesi, Olufunmilayo A ^c   Anumudu, Chiaka I ^d   Hainaut, Pierre ^e   Gormally, Emmanuelle ^f  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b OBAFEMI AWOLOWO UNIVERSITY TEACHING HOSPITALS COMPLEX   (Nigeria)

^c LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e Molecular Carcinogenesis Unit

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cell free plasma DNA; Hepatocellular carcinoma; Nigeria; p53 codon 249 mutation

Indexed keywords

GENOMIC DNA; PROTEIN P53;

ADULT; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CELL FREE SYSTEM; CLINICAL EXAMINATION; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; HUMAN; INTERVIEW; LABORATORY TEST; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NIGERIA; PATIENT ASSESSMENT; PREVALENCE; QUESTIONNAIRE; RADIODIAGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 56749101724     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31834-4     Document Type: Article

References (34)

1. Waterhouse JAH, Muir CS, Correa P, Powell J. Cancer incidence in five continents. IV. IARC Scientific Publication 1982: 42.
2. Bosch FX, Ribes J, Boras J. Epidemiology of primary liver cancer. Semin Liver Disease 1999; 19: 271-285.
3. Huang ZH, Sun LH, Lu DD, Sun Y, Ma LJ, et al. Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China. World J Gastroenterol 2003; 4: 692-695 http://www.cancerprev.org/Journal/Issues/ 18/2/13 2002
4. Olubuyide IO, Ayoola EA, Atoba M. Hepatobiliary disease in tropical Africa - the Ibadan experience. Trop Gastroenterology 1986; 7: 54-60.
5. Atoba MA, Olubuyide IO, Aghadiuno PO. Gastrointestinal malignancies in a tropical African population. Trop Doctor 1989; 19: 135-137.
6. Otegbayo JA, Oluwasola OA, Akere A, Ogunbiyi JO. Temporal and biological trends in liver cancers at a University hospital in Southwest Nigeria. Trop Doctor 2006; 36: 28-30.
7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-430.
8. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003; 38: 136-149.
9. Debuire B, Lemoine A. Liver: Hepatocellular carcinoma. Atlas Genet and Cytogenet Oncol Haematol 2001. http://www.Infobiogen.fr/services/ chromancer/Tumours/HepatocarcinID5039.htm.
10. Jackson PE, Kuang SY, Wang JB, Strickland PT, Muñoz A, et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 2003; 24: 1657-1663.
11. Szymanska K, Lesi OA, Kirk GD, Sam O, Taniere P, et al. Ser-TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer 2004; 110: 374-379.
12. Wong N, Lai P, Pang E, Fung L, Sheng Z, et al. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin Cancer Res 2000; 6: 4000-4009.
13. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991; 338: 1356-1359.
14. Coursaget P, Depril N, Chabaud M, Nandi R, Mayelo V, et al. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br J Cancer 1993; 67: 1395-1397.
15. Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia. Journal of the National Cancer Institute 2000; 92: 148-153.
16. Ndububa DA, Yakicier CM, Ojo OS, Adeodu OO, Rotimi O, et al. p53 codon 249 mutation in hepatocellular carcinomas from Nigeria. Afr J Med Med Sci 2001; 30: 125-127.
17. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999; 18: 65-73.
18. ser-Mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev 2005; 14: 2956-2962.
19. International Agency For Research on Cancer (IARC). Hapatitis viruses. Lyon (France); IARC Monogr Eval Carcinog Risks Hum, 59: 1994
20. International Agency For Research on Cancer (IARC). Some naturally occurring substances: Food items and constituents, heterocyclic aromatic amines and mycotoxins. Lyon (France); IARC Monogr Eval Carcinog Risks Hum 1993; 56: 245-395.
21. Olubuyide IO, Maxwell SM, Akinyinka OO, Hart CA, Neal GE, et al. HBsAg and aflatoxins in sera of rural (Igbo-Ora) and urban (Ibadan) populations in Nigeria. Afr J Med Med Sci 1993; 22: 77-80.
22. Nwokolo C, Okonkwo I. Aflatoxin load of common food in savanna and forest regions of Nigeria. Transactions of the Royal Society of Trop Med and Hyg 1978; 72: 329-332.
23. Atawodi SE, Atiku AA, Lamorde AG. Aflatoixn contamination of Nigerian foods and feeding stuffs. Fd Chem Toxic 1993; 32: 61-63.
24. Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, et al. 249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 2005; 24: 5858-5867.
25. Wang G, Chang HH, Yan Z, Ling C, Ying W, et al. Genetic aberration in primary hepatocellular carcinoma: correlation between p53 gene mutation and loss-of-heterozygosity on chromosome 16q21-q23 and 9p21-p23. Cell Research 2000; 10: 311-323.
26. Rashid A, Wang JS, Quian GS, Lu BX, Hamilton SR, et al. Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. Br J Cancer 1999; 80: 59-66.
27. McGlynn KA, Rosevold EA, Lustbader ED, Hu Y, Clapper ML, et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995; 92: 2384-2387.
28. Stern MC, Umbach DM, Yu CM, London SJ, Zhang ZQ, et al. Hepatitis B, Aflatoxin B1, and p53 Codon 249 Mutation in Hepatocellular Carcinomas from Guangxi, People's Republic of China, and a Meta-analysis of Existing Studies. Cancer Epidemiology Biomarkers & Prevention 2001; 10: 617-625
29. Akere A, Otegbayo JA. Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma. Singapore Med J 2007; 48: 41-44.
30. Imer DJ, Olomu A, Skidmore S, Olomu N, Rarcliffe D, et al. Viral hepatitis in Nigeria % sickle-cell disease and commercial blood donors. Quarterly Journal of Medicine 1994; 87: 407-411.
31. Otegbayo JA, Arinola OG, Aje OA, Oluwasola OA, Okiwelu OH, et al. Usefulness of acute phase proteins for monitoring development of hepatocellular carcinoma in hepatitis B virus carriers. West African J Med 2005; 24: 124-127.
32. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34: 603-605.
33. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systemic review. Hepatology 2002; 36: S84-S92.
34. Ola SO, Olubuyide IO, Ayoola EA. serum alpha-fetoprotein, hepatitis B virus infection and primary hepatocellular carcinoma in Nigerians. East African Medical Journal 1994; 71: 782-783.